Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Joanna Sawczuk-Chabin"'
Publikováno v:
Hematologia. 11:253-258
The development of targeted therapies in AML patients enabling treatment individualization, such as new FLT3 tyrosine kinase inhibitors, is a promising option for improving treatment outcomes and prolonging patient survival. However, the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99394cca99714a459406a21d36c21c44
https://doi.org/10.5603/hem.2020.0045
https://doi.org/10.5603/hem.2020.0045
Autor:
Sylwia Oborska, Sebastian Giebel, Tomasz Ogórka, Michal Osowiecki, Paweł Steckiewicz, Magdalena Maruszak, Łukasz Targoński, Michał Taszner, Joanna Romejko-Jarosinska, Anna Czyż, Joanna Drozd-Sokołowska, Joanna Sawczuk-Chabin, Jarosław Dybko, Joanna Mańko, Wojciech Legiec, Ewa Paszkiewicz-Kozik, Maria Saduś-Wojciechowska, Anna Ejduk, Agata Szymańska
Publikováno v:
Acta Haematologica Polonica. 49:234-239
Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74f6b31a55ae8d8e6c5203b62ffb4bd
https://doi.org/10.2478/ahp-2018-0027
https://doi.org/10.2478/ahp-2018-0027
Publikováno v:
Hematologia. 7:312-326
The long term prognosis of adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. There is no standard treatment for relapsed ALL and reinduction therapy should only be a “bridge treatment” in allogeneic hemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a293fa599420fbcdeb45acda424a327
https://doi.org/10.5603/hem.2016.0030
https://doi.org/10.5603/hem.2016.0030
Autor:
Joanna Sawczuk-Chabin, Elżbieta Kisiel, Wojciech Jurczak, Wanda Knopinska-Posluszny, Piotr Centkowski, Omeir Khan
Publikováno v:
Contemporary Oncology
Aim of the study To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL. Material and methods Patients with primary refractory or high-risk DLBCL (n = 18), ineligible fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0440666f08737206049641df48f5b932
https://doi.org/10.5114/wo.2015.50012
https://doi.org/10.5114/wo.2015.50012
Publikováno v:
Leukemia & Lymphoma. 46:471-475
We describe the case of a 47-year-old man admitted to the Department of Hematology because of fever, enlarged cervical and supraclavicular lymph nodes, hepatosplenomegaly and non-specific lung infiltrations. The histopathological examination of the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db9c78f0bf5d99223de81590559daa4
https://doi.org/10.1080/10428190400019891
https://doi.org/10.1080/10428190400019891
Autor:
Kazimierz Sulek, Piotr Centkowski, Lech Konopka, Bernadeta Ceglarek, Katarzyna Budziszewska, Joanna Sawczuk-Chabin, Jacek Najda, Jerzy Holowiecki, Maria Blasinska-Morawiec, Ewa Kalinka, Krzysztof Warzocha
Publikováno v:
Blood. 106:4738-4738
The purpose of the study was to evaluate response, duration of response, and toxicity of fludarabine (F), mitoxantrone (M), and dexamethason (D) (FMD) in patients (pts) with relapsed or refractory low-grade non-Hodgkin lymphoma (LGNHL). 26 pts with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caea4a146bbf47b4d8547c05f1772786
https://doi.org/10.1182/blood.v106.11.4738.4738
https://doi.org/10.1182/blood.v106.11.4738.4738
Autor:
Ilona Seferynska, Joanna Sawczuk-Chabin, Bernadetta Ceglarek, Maria Blasinska-Morawiec, Kazimierz Sulek, Lech Konopka, Jaroslaw Wajs, Piotr Centkowski, Krzysztof Warzocha, Tadeusz Robak, Ewa Kalinka
Publikováno v:
ResearcherID
The aim of the study was to comparatively assess first-line treatment with cladribine alone or in combination with cyclophosphamide (CCR, cladribine-containing regimens) and COP (cyclophosphamide, vincristine, prednisone) in different subtypes of low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fd9036d5357d048cb39575727798f9
https://doi.org/10.1182/blood.v106.11.4739.4739
https://doi.org/10.1182/blood.v106.11.4739.4739
Autor:
Piotr Centkowski, Lidia Brydak, Magdalena MachaLa, Ewa Kalinka-Warzocha, Maria BLAsiNSka-Morawiec, Irena Federowicz, Jan Walewski, Joanna Wc{E}?>Grzyn, Dariusz WoLOwiec, Ewa Lech-MaraNDa, Joanna Sawczuk-Chabin, PrzemysLAw BiliNSki
Publikováno v:
Journal of Clinical Immunology; May2007, Vol. 27 Issue 3, p339-346, 8p
Autor:
Iwona Solarska, Joanna Sawczuk-Chabin, Ilona Seferynska, Piotr Centkowski, Monika Prochorec-Sobieszek, Krzysztof Warzocha, Miroslaw Majewski, Joanna Dobrzanska
Publikováno v:
ResearcherID
A feature that distinguishes chronic idiopathic myelofibrosis (CIM) from other chronic myeloproliferative disorders is the progression to bone marrow fibrosis and osteosclerosis. Because osteoclast formation can be inhibited by osteoprotegerin (OPG),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba562a840f2fcf7ab9b8dab58fca788f
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426102057&KeyUID=WOS:000233426102057
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426102057&KeyUID=WOS:000233426102057
Autor:
Joanna Sawczuk-Chabin, Jan Walewski, Krzysztof Warzocha, Ewa Kalinka, Aleksander B. Skotnicki, Maria Blasinska-Morawiec, Przemysław Biliński, Irena Federowicz, Piotr Centkowski, Lidia B Brydak, Magdalena Machała, Dariusz Wołowiec, Joanna Wegrzyn
Publikováno v:
ResearcherID
We assessed humoral response to influenza vaccination (vacc) in two consecutive seasons 2003/2004 and 2004/2005 in 123 NHL patients. In season 03/04 50 patients (29 previously treated with chemotherapy - group A03/04 and 21 not treated - group B03/04
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aafc4b38354078fce9e6950c8bbb6ecf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426101387&KeyUID=WOS:000233426101387
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426101387&KeyUID=WOS:000233426101387